Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 18Terminated 5Active not recruiting 5Recruiting 3Withdrawn 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Lymphoid 2Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 16Myelodysplastic Syndromes 12Multiple Myeloma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Hematologic Neoplasms 6Neuroblastoma 5Hodgkin Disease 5Retinoblastoma 4Lymphoma, Non-Hodgkin 4Graft vs Host Disease 4Anemia, Refractory, with Excess of Blasts 4Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Chronic 3Recurrence 2Primary Myelofibrosis 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Biphenotypic, Acute 2Leukemia, B-Cell 2Leukemia 2Ganglioneuroblastoma 2Anemia, Aplastic 2beta-Thalassemia 1Venentoclax 1Thrombocythemia, Essential 1Sarcoma, Ewing 1Rhabdomyosarcoma 1

Interventions

fludarabine 8Specimen Handling 8Cyclophosphamide 7ruxolitinib 5Whole-Body Irradiation 5Stem Cell Transplantation 5Biopsy 5Azacitidine 5venetoclax 4Tacrolimus 4Injections 4Cytarabine 4Busulfan 4ivosidenib 3fludarabine phosphate 3Thiotepa 3Mycophenolic Acid 3Melphalan 3Cyclosporins 3CPX-351 3Blood Specimen Collection 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3luspatercept 2X-Rays 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Liposomes 2Gemtuzumab 2Daunorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Myeloproliferative Disorders × Melphalan × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT06815003 2025-06-27

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center

Phase 2 Recruiting
35 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03852407 2022-10-12

HLA

University of Liege

Phase 2 Recruiting
114 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, B-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡